Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease

NCT03615924 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
193
Enrollment
INDUSTRY
Sponsor class

Stopped Recommendation from an independent data monitoring committee (DMC) and accepted by AstraZeneca.

Conditions

Interventions

Sponsor

AstraZeneca

Collaborators